Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents

Tyler Maclay, Joseph Vacca, Casey McComas, Alfredo Castro, Melinda Day, PhD, Kevin Mills, PhD

Blood (2018) 132 (Supplement 1): 3963.

https://doi.org/10.1182/blood-2018-99-119373

Published: 2018

Journal Articles

Preliminary Safety, Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of the Polo-like Kinase-1 (PLK1) Inhibitor PCM-075, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (D) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Alexander I Spira, MD, Prapti A. Patel, MD, Michaela L. Tsai, MD, Maya Ridinger, PhD, Sandra L Silberman, MD PhD, Mark Erlander, PhD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 4043.

https://doi.org/10.1182/blood-2018-99-112590

Published: 2018

Journal Articles

Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions

Sara R. Vazquez

Blood (2018) 132 (21): 2230–2239.

https://doi.org/10.1182/blood-2018-06-848747

Published: 2018

Journal Articles

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

Leylah M. Drusbosky, PhD, Ansu Kumar, MS, Shwetha K, BE, Priyanka Bhargav, BE, Ashish Choudhary, MS, Soumyashree L, BE, Shivgonda C. Birajdar, MCA, Kunal Ghosh Roy, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Manju Sengar, MD DM, Girish Chinnaswamy, MD MRCP, Bijal D. Shah, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 2708.

https://doi.org/10.1182/blood.V130.Suppl_1.2708.2708

Published: 2017

Journal Articles

CYP3A-Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib

Raquel Izumi, PhD, Paul G. Pearson, PhD, Ahmed Hamdy, MD, Sara Rodriquez, MHA, Yolanda Y.L. Yang, MD PhD, Roger G. Ulrich, PhD, Terry Podoll, PhD, Marilee Andrew, PhD, Cecile M. Krejsa, PhD, Tim Ingallinera, BSc, J. Greg Slatter, PhD

Blood (2017) 130 (Supplement 1): 4996.

https://doi.org/10.1182/blood.V130.Suppl_1.4996.4996

Published: 2017

Journal Articles

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

Jan de Jong, PhD, Peter Hellemans, MD, Severijn De Wilde, Daniel Patricia, Tara Masterson, Georgii Manikhas, MD PhD, Alexander Myasnikov, MD PhD, Dzhelil Osmanov, MD, Raul Cordoba, MD PhD, Carlos Panizo, Loeckie de Zwart, PhD, Jan Snoeys, PhD, Vijay Chauhan, PhD, James Jiao, PhD, Juthamas Sukbuntherng, PhD, Daniele Ouellet, PhD

Blood (2016) 128 (22): 3964.

https://doi.org/10.1182/blood.V128.22.3964.3964

Published: 2016

Journal Articles

An Open-Label, Sequential-Design Drug Interaction Study of the Effects of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

Jan de Jong, PhD, Peter Hellemans, MD, James Jiao, PhD, Juthamas Sukbuntherng, PhD, Daniele Ouellet, PhD

Blood (2016) 128 (22): 1588.

https://doi.org/10.1182/blood.V128.22.1588.1588

Published: 2016

Journal Articles

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry

Joanna Gora-Tybor, Tomasz Sacha, Joanna Waclaw, Joanna Niesiobedzka, Olga Grzybowska-Izydorczyk, Ewa Medras, Izabela Deren-Wagemann, Elzbieta Patkowska, Ilona Seferynska, Krzysztof Lewandowski, Anna Wache, Beata Blajer-Olszewska, Marzena Watek, Krzysztof Warzocha, Krzysztof Jamroziak

Blood (2016) 128 (22): 1909.

https://doi.org/10.1182/blood.V128.22.1909.1909

Published: 2016

Journal Articles

Investigating Effects of Cyclosporine on Eltrombopag Pharmacokinetics in Healthy Volunteers: A Phase 1 Crossover, Drug-Drug Interaction Study

Jianping Zhang, PhD, Connie L. Erickson-Miller, PhD, Geoffrey Chan, MD, Yan Yan Zhou, PhD

Blood (2015) 126 (23): 4791.

https://doi.org/10.1182/blood.V126.23.4791.4791

Published: 2015

Journal Articles

Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma

Dirk Daelemans, PhD, Eline Boons, Els Vanstreels, Maarten Jacquemyn, Tatiane C Nogueira, Jasper E Neggers, Thomas Vercruysse, Joost van den Oord, Sharon Tamir, Michael Kauffman, MD PhD, Sharon Shacham, Yosef Landesman, PhD, Robert Snoeck, Christophe Pannecouque, Graciela Andrei

Blood (2015) 126 (23): 2751.

https://doi.org/10.1182/blood.V126.23.2751.2751

Published: 2015

Journal Articles

Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs

Shermin Sayani, BS, Omer Iqbal, MD, Debra Hoppensteadt, PhD, Jawed Fareed, PhD

Blood (2014) 124 (21): 4267.

https://doi.org/10.1182/blood.V124.21.4267.4267

Published: 2014

Journal Articles

Evaluation Of CYP450 and Transporter-Mediated Drug-Drug Interaction Potential Of Pomalidomide In Healthy Men and In Vitro

Claudia Kasserra, PhD, Mahmoud Assaf, MS, MBA, Matthew Hoffmann, PhD, Yan Li, PhD, Liangang Liu, PhD, Xiaomin Wang, PhD, Gondi Kumar, PhD, Maria Palmisano, MD

Blood (2013) 122 (21): 1989.

https://doi.org/10.1182/blood.V122.21.1989.1989

Published: 2013

Journal Articles

Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Candra Moyer, Sibylle Wilbert, PhD, Bernard Murray, PhD, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5574.

https://doi.org/10.1182/blood.V122.21.5574.5574

Published: 2013

Journal Articles

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

Yan Xin, PhD, Lixin Shao, MD MS, Wei Deng, PhD, Amanda Shaffer, Pharm D, Dimitrios Stefanidis, PhD, Jeffrey Hemenway, PhD, Xiaoming Li, PhD, Susie Jun, MD, PhD, Srini Ramanathan, PhD

Blood (2013) 122 (21): 5239.

https://doi.org/10.1182/blood.V122.21.5239.5239

Published: 2013

Journal Articles

A Phase 1, Open Label Study To Evaluate The Drug Interaction Potential With Ketoconazole and The Effect Of Food On The Plasma Pharmacokinetics Of The Smoothened Inhibitor PF-04449913

M.Naveed Shaik, PhD, Robert R LaBadie, MPH, Dan Rudin, MD, Wendy J. Levin, MD, MS

Blood (2013) 122 (21): 3857.

https://doi.org/10.1182/blood.V122.21.3857.3857

Published: 2013

Journal Articles

Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus

Nianhang Chen, PhD, Daniel Weiss, MD, Josephine Reyes, DVM, Liangang Liu, PhD, Claudia Kasserra, PhD, Xiaomin Wang, PhD, Simon Zhou, PhD, Gondi Kumar, PhD, Lilia Weiss, MD, Maria Palmisano, MD

Blood (2013) 122 (21): 5395.

https://doi.org/10.1182/blood.V122.21.5395.5395

Published: 2013

Journal Articles

Analysis Of Warfarin Drug-Drug Interactions With Antibiotics In The Ambulatory Care Setting

Nathan P Clark, PharmD, FCCP, BCPS, Thomas Delate, PhD, MS, Catherine S Riggs, PharmD, Daniel M Witt, PharmD, FCCP, BCPS, Elaine M Hylek, MD, David A Garcia, MD, Walter Ageno, MD, Francesco Dentali, MD, Mark A. Crowther, MD, MSc, FRCPC

Blood (2013) 122 (21): 1143.

https://doi.org/10.1182/blood.V122.21.1143.1143

Published: 2013

Journal Articles

Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

Johan Maertens, MD, PhD, Michael Lübbert, MD, Walter Fiedler, MD, Loic Fouillard, Alf Haaland, MD, Joseph M. Brandwein, MD, Stéphane Lepretre, MD, Oumédaly Reman, MD, Pascal Turlure, MD, Gesine Bug, Carsten Müller-Tidow, Alwin Krämer, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Hartmut Döhner, MD

Blood (2012) 120 (21): 411.

https://doi.org/10.1182/blood.V120.21.411.411

Published: 2012

Journal Articles

Drug-Drug Interactions in the Hematology and Oncology Department: A Real-Life Assessment of Frequency and Severity

Barbara Metzke, Martin J Hug, PhD, Geertje Fink, MD, Stefanie Hieke, Manfred Jung, PhD, Monika Engelhardt

Blood (2012) 120 (21): 4250.

https://doi.org/10.1182/blood.V120.21.4250.4250

Published: 2012

Journal Articles

Effect of New Direct Oral Anticoagulants on Ex Vivo Platelet and Fibrin Thrombus Formation in Blood Flowing Over Fibrillar Type I Collagen

Grazia Loredana Mendolicchio, MD, PhD, Corrado Lodigiani, MD, Monica Bacci, Marco Scardino, MD, Carlo Ferrari Matteo, MD, Grappiolo Guido, MD, Lidia Rota, MD, Zaverio M. Ruggeri, MD

Blood (2011) 118 (21): 2318.

https://doi.org/10.1182/blood.V118.21.2318.2318

Published: 2011

NARROW

CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents

Preliminary Safety, Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of the Polo-like Kinase-1 (PLK1) Inhibitor PCM-075, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (D) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions

Predictive Simulation Modeling of Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Patient Genomics Identifies Targeted Combination Treatment Options

CYP3A-Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

An Open-Label, Sequential-Design Drug Interaction Study of the Effects of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults

Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry

Investigating Effects of Cyclosporine on Eltrombopag Pharmacokinetics in Healthy Volunteers: A Phase 1 Crossover, Drug-Drug Interaction Study

Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma

Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs

Evaluation Of CYP450 and Transporter-Mediated Drug-Drug Interaction Potential Of Pomalidomide In Healthy Men and In Vitro

Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

The Relative Bioavailability, Food Effect and Drug Interaction With Omeprazole Of Momelotinib Tablet Formulation

A Phase 1, Open Label Study To Evaluate The Drug Interaction Potential With Ketoconazole and The Effect Of Food On The Plasma Pharmacokinetics Of The Smoothened Inhibitor PF-04449913

Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus

Analysis Of Warfarin Drug-Drug Interactions With Antibiotics In The Ambulatory Care Setting

Drug-Drug Interactions in the Hematology and Oncology Department: A Real-Life Assessment of Frequency and Severity

Effect of New Direct Oral Anticoagulants on Ex Vivo Platelet and Fibrin Thrombus Formation in Blood Flowing Over Fibrillar Type I Collagen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only